DGAP-News: Neovacs announces its engagement in the field of immunotherapy in cancer, following the recommendation of its Scientific Advisory Board which met in New York on the 17th of November


DGAP-News: Neovacs S.A. / Key word(s): Strategic Company Decision
Neovacs announces its engagement in the field of immunotherapy in cancer,
following the recommendation of its Scientific Advisory Board which met in
New York on the 17th of November

01.12.2015 / 08:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Neovacs announces its engagement in the field of immunotherapy in cancer,
following the recommendation of its Scientific Advisory Board which met in
New York on the 17th of November.

Paris and Boston, December 1st, 2015 - NEOVACS (Alternext Paris: ALNEV), a
leader in active immunotherapies for the treatment of autoimmune diseases,
announced today its engagement into the field of immuno-oncology. The
decision is based on recommendations by the Company's Scientific Adivsory
Board, which met on November 17, 2015 in New York.

Neovacs convened its Scientific Advisory Board  with the clear mission to
identify novel cytokine/growth factor targets in oncology. Neovacs'
proprietary technology is based on active immunotherapy, which stimulates a
patients immune system to produce polyclonal antibodies, neutralizing
pathogenic proteins.

As a result of their work, the Scientific Advisory Board recommended
Neovacs to focus on the preclinical development of specific Kinoid's
targeting:

The Neutralization of tumoral growth factors including VEGF-A in different
types of cancer, in particular colorectal cancer and ovarian cancers. 

In phase I/II trial the Company's IFNα Kinoid demonstrated in lupus
patients its ability to obtain:

  - A strong immune response in 100% of the patients (21/21 exposed to
    IFN-K)

  - A high level of neutralizing antibodies in the patients at the highest
    doses

  - A reduction of the IFN gene signature to the base level 

  - Six patients from the trial were followed up for a median duration of 3
    years by Neovacs, because they still have persisting anti IFNα
    antibodies. These six patients had no flares during this period.

Considering this capacity of the Kinoids to inhance a strong immune
response, the scientific advisory board met under the chairmanship of Prof.
Jacques BANCHEREAU, Director for Immunological Science, Jackson Laboratory
for Genomic Medicine, Farmington, Conn.

The following scientists participated in this meeting:

  - Prof. Tanios Bekali-SAAB, MD, Section Chief of Gastrointestinal
Oncology,
    Professor of Medecine & Pharmacy, The Ohio State University Cancer
    Hospital, Ohio

  - Prof. Maura N. DICKLER, MD, Medical Oncologist, Memorial Sloan
    Kettering Cancer Center, New York

  - Prof. Robert S. KERBEL, PhD, Senior Scientist and Professor, Sunnybrook
    Research Institute, Biological Sciences Platform, and Dept. of Medical
    Biophysics,University of Toronto, Canada

  - Prof. Miriam MERAD, MD, PhD, Professor of Oncological Science, Medicine
    and Immunology Tisch Cancer Institute , Icahn School of Medicine at
    Mount Sinai, New York

  - Prof. Virginia PASCUAL, MD, Director, Center for Inflammatory and
    Autoimmune  Diseases, Baylor Institute, Dallas, Texas

  - Prof. Richard T. PENSON, MD, MRCP, Associate Professor, Medecine,
    Harvard Medical School, Clinical Director for  Medical Gynecologic
    Oncology, Boston, MA

  - Prof. Laurence ZITVOGEL, MD, PhD, Director of INSERM U1015, Head of
    Dpt. of Cancer Immunology and Immunotherapy at Institut Gustave Roussy,
    Villejuif, France

This program on oncology will be pursued in close cooperation with Prof.
Robert S. Kerbel, and the Sunnybrook Research Institute, Toronto, Canada.
The objective is to obtain proof of concept in relevant preclinical models
in the course of 2016, before initiating clinical trials. These studies
will be funded within actual cash on-hand.


About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus and dermatomyositis. Neovacs is
also conducting preclinical development works on other therapeutic vaccines
in the fields of autoimmune diseases, oncology and allergies. The goal of
the Kinoid approach is to enable patients to have access to safe treatments
with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr

Contacts 

NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 00
cmasson@neovacs.com

Investor Relations / Financial Communications - NewCap 
Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
neovacs@newcap.fr

Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu

Press / U.S. Inquiries - The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
 lroth@theruthgroup.com / jgreen@theruthgroup.com


---------------------------------------------------------------------------

01.12.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


   Language:    English                                                   
   Company:     Neovacs S.A.                                              
                3-5, Impasse Reille                                       
                75014 Paris                                               
                France                                                    
   Phone:       +33 (0)1 53 10 93 00                                      
   Fax:         +33 (0)1 53 10 93 03                                      
   E-mail:      www.neovacs.fr                                            
   Internet:    info@neovacs.fr                                           
   ISIN:        FR0004032746                                              
   WKN:         A1CVKR                                                    
   Listed:      Regulated Unofficial Market in Stuttgart; Open Market in  
                Frankfurt                                                 
 
 
   End of News    DGAP News Service  
---------------------------------------------------------------------------

419633 01.12.2015